Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of sarcoma that occur spontaneously or in association with neurofibromatosis type 1 (NF-1). This study aimed to clinically differentiate these types of MPNSTs. Materials and Methods The study reviewed 95 patients diagnosed with and treated for MPNST at Yonsei University Health System, Seoul, Korea over a 27-year period. The clinical characteristics, prognostic factors, and treatment outcomes of sporadic MPNST (sMPNST) and NF-1 associated MPNST (NF-MPNST) cases were compared. Results Patients with NF-MPNST had a significantly lower median age (32 years vs. 45 years for sMPNST, p=0.012), significantly larger median tumor size (8.2 cm vs. 5.0 cm for sMPNST, p < 0.001), and significantly larger numbers of imaging studies and surgeries (p=0.004 and p < 0.001, respectively). The 10-year overall survival (OS) rate of the patients with MPNST was 52±6%. Among the patients with localized MPNST, patients with NF-MPNST had a significantly lower 10-year OS rate (45±11% vs. 60±8% for sMPNST, p=0.046). Univariate analysis revealed the resection margin, pathology grade, and metastasis to be significant factors affecting the OS (p=0.001, p=0.020, and p < 0.001, respectively). Multivariate analysis of the patients with localized MPNST identified R2 resection and G1 as significant prognostic factors for OS. Conclusion NF-MPNST has different clinical features from sMPNST and requires more careful management. Further study will be needed to develop specific management plans for NF-MPNST.
Abstract
Purpose Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of sarcoma that occur spontaneously or in association with neurofibromatosis type 1 (NF-1). This study aimed to clinically differentiate these types of MPNSTs. Materials and Methods The study reviewed 95 patients diagnosed with and treated for MPNST at Yonsei University Health System, Seoul, Korea over a 27-year period. The clinical characteristics, prognostic factors, and treatment outcomes of sporadic MPNST (sMPNST) and NF-1 associated MPNST (NF-MPNST) cases were compared. Results Patients with NF-MPNST had a significantly lower median age (32 years vs. 45 years for sMPNST, p=0.012), significantly larger median tumor size (8.2 cm vs. 5.0 cm for sMPNST, p < 0.001), and significantly larger numbers of imaging studies and surgeries (p=0.004 and p < 0.001, respectively). The 10-year overall survival (OS) rate of the patients with MPNST was 52±6%. Among the patients with localized MPNST, patients with NF-MPNST had a significantly lower 10-year OS rate (45±11% vs. 60±8% for sMPNST, p=0.046). Univariate analysis revealed the resection margin, pathology grade, and metastasis to be significant factors affecting the OS (p=0.001, p=0.020, and p < 0.001, respectively). Multivariate analysis of the patients with localized MPNST identified R2 resection and G1 as significant prognostic factors for OS. Conclusion NF-MPNST has different clinical features from sMPNST and requires more careful management. Further study will be needed to develop specific management plans for NF-MPNST.
참고문헌 (30)
- Amirian ES, "Pediatric and adult malignant peripheral nerve sheath tumors : an analysis of data from the surveillance, epidemiology, and end results program", J Neurooncol, 116, pp.609~616 (2014)
- Tucker T, "Association between benign and malignant peripheral nerve sheath tumors in NF1", Neurology, 65, pp.205~211 (2005)
- Ferner RE, "International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis", Cancer Res, 62, pp.1573~1577 (2002)
- Baehring JM, "Malignant peripheral nerve sheath tumor : the clinical spectrum and outcome of treatment", Neurology, 61, pp.696~698 (2003)
- Carli M, "Pediatric malignant peripheral nerve sheath tumor : the Italian and German soft tissue sarcoma cooperative group", J Clin Oncol, 23, pp.8422~8430 (2005)
- Stucky CC, "Malignant peripheral nerve sheath tumors(MPNST) : the Mayo Clinic experience", Ann Surg Oncol, 19, pp.878~885 (2012)
- LaFemina J, "Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors", Ann Surg Oncol, 20, pp.66~72 (2013)
- Hirbe AC, "Neurofibromatosis type 1 : a multidisciplinary approach to care", Lancet Neurol, 13, pp.834~843 (2014)
- DeBella K, "Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children", Pediatrics, 105(3 Pt 1), pp.608~614 (2000)
- Gutmann DH, "Somatic neurofibromatosis type 1(NF1)inactivation characterizes NF1-associated pilocytic astrocytoma", Genome Res, 23, pp.431~439 (2013)
- Porter DE, "Survival in malignant peripheral nerve sheath tumours : a comparison between sporadic and neurofibromatosis type 1-associated tumours", Sarcoma, 2009, pp.756395~ (2009)
- Kolberg M, "Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1", Neuro Oncol, 15, pp.135~147 (2013)
- Cashen DV, "Survival data for patients with malignant schwannoma", Clin Orthop Relat Res, (426), pp.69~73 (2004)
- Yu J, "Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor", Clin Cancer Res, 17, pp.1924~1934 (2011)
- Anghileri M, "Malignant peripheral nerve sheath tumors : prognostic factors and survival in a series of patients treated at a single institution", Cancer, 107, pp.1065~1074 (2006)
- Zou C, "Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome", Ann Surg, 249, pp.1014~1022 (2009)
- Deyrup AT, "Grading of soft tissue sarcomas : the challenge of providing precise information in an imprecise world", Histopathology, 48, pp.42~50 (2006)
- Edge SB, "The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Zehou O, "Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1 : a 10-year institutional review", Orphanet J Rare Dis, 8, pp.127~ (2013)
- Evans DG, "Malignant peripheral nerve sheath tumours in neurofibromatosis 1", J Med Genet, 39, pp.311~314 (2002)
- deCou JM, "Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience", Ann Surg Oncol, 2, pp.524~529 (1995)
- Hegedus B, "Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma", Cancer Res, 68, pp.1520~1528 (2008)
- Kahn J, "Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors", Front Oncol, 4, pp.324~ (2014)
- Sordillo PP, "Malignant schwannoma : clinical characteristics, survival, and response to therapy", Cancer, 47, pp.2503~2509 (1981)
- Ducatman BS, "Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases", Cancer, 57, pp.2006~2021 (1986)
- Korf BR, "Malignancy in neurofibromatosis type 1", Oncologist, 5, pp.477~485 (2000)
- Meehan RS, "New treatment option for ovarian cancer : PARP inhibitors", Gynecol Oncol Res Pract, 3, pp.3~ (2016)
- Curatolo P, "Neurological and neuropsychiatric aspects of tuberous sclerosis complex", Lancet Neurol, 14, pp.733~745 (2015)
- Colman SD, "Benign neurofibromas in type 1 neurofibromatosis(NF1)show somatic deletions of the NF1 gene", Nat Genet, 11, pp.90~92 (1995)
- Carroll SL, "The challenge of cancer genomics in rare nervous system neoplasms : malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics", Am J Pathol, 186, pp.464~477 (2016)